Covered recipient · General Payments record
EMILY ANNE XIN TRIPP
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Women's Health
General Payments · PY2025
$269.52
- Reported across 14 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $269.52 | 14 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $75.27 | 4 |
| Exeltis, USA Inc. | $53.03 | 3 |
| Novo Nordisk AS | $36.99 | 2 |
| Sumitomo Pharma America, Inc. | $29.00 | 2 |
| Astellas Pharma US Inc | $28.93 | 1 |
| VERTEX PHARMACEUTICALS INCORPORATED | $24.01 | 1 |
| MILLICENT US INC | $22.29 | 1 |
By program year
All program years on this page · sorted by year
| Program year | Amount | Records |
|---|---|---|
| PY2025 | $269.52 | 14 |
Payment records · PY2025 (14)
Ordering applied by this site (paying entity, then date) · record values are shown as CMS published them
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Astellas Pharma US Inc | $28.93 | 12/11/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1238617570 | CMS |
| Exeltis, USA Inc. | $17.86 | 07/10/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1218223192 | CMS |
| Exeltis, USA Inc. | $14.57 | 09/15/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1218223194 | CMS |
| Exeltis, USA Inc. | $20.60 | 11/14/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1218223196 | CMS |
| Lilly USA, LLC | $20.18 | 04/25/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1187023988 | CMS |
| Lilly USA, LLC | $18.96 | 05/19/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1187105269 | CMS |
| Lilly USA, LLC | $17.00 | 07/25/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1187031265 | CMS |
| Lilly USA, LLC | $19.13 | 09/18/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1187042213 | CMS |
| MILLICENT US INC | $22.29 | 06/13/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1235214635 | CMS |
| Novo Nordisk Inc | $15.49 | 07/17/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188316753 | CMS |
| Novo Nordisk Inc | $21.50 | 11/03/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188536044 | CMS |
| Sumitomo Pharma America, Inc. | $15.10 | 10/30/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1176807953 | CMS |
| Sumitomo Pharma America, Inc. | $13.90 | 12/09/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1176807955 | CMS |
| VERTEX PHARMACEUTICALS INCORPORATED | $24.01 | 07/29/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1213884127 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2025
- Source files
- Dataset page · Bulk file · PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.